Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer.

Chowdhury P, Nagesh PKB, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM.

Acta Pharm Sin B. 2018 Jul;8(4):602-614. doi: 10.1016/j.apsb.2017.10.004. Epub 2017 Dec 10.

2.

Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells.

Hatami E, Nagesh PKB, Chowdhury P, Chauhan SC, Jaggi M, Samarasinghe AE, Yallapu MM.

Pharmaceutics. 2018 Aug 1;10(3). pii: E111. doi: 10.3390/pharmaceutics10030111.

3.

Nano-hydroxyapatite polymeric hydrogels for dye removal.

Varaprasad K, Nunez D, Yallapu MM, Jayaramudu T, Elgueta E, Oyarzun P.

RSC Adv. 2018 May 16;8(32):18118-18127. doi: 10.1039/c8ra01887a. Epub 2018 May 17.

4.

Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.

Kumar BNP, Puvvada N, Rajput S, Sarkar S, Mahto MK, Yallapu MM, Pathak A, Emdad L, Das SK, Reis RL, Kundu SC, Fisher PB, Mandal M.

Mol Pharm. 2018 Jul 2;15(7):2698-2713. doi: 10.1021/acs.molpharmaceut.8b00218. Epub 2018 May 30.

PMID:
29787277
5.

Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.

Tripathi MK, Doxtater K, Keramatnia F, Zacheaus C, Yallapu MM, Jaggi M, Chauhan SC.

Drug Discov Today. 2018 Apr 23. pii: S1359-6446(18)30071-0. doi: 10.1016/j.drudis.2018.04.010. [Epub ahead of print] Review.

PMID:
29698834
6.

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Chauhan SC.

Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32. doi: 10.3390/ph11020032. Review.

7.

Tannic Acid Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Prostate Cancer.

Nagesh PKB, Hatami E, Chowdhury P, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM.

Cancers (Basel). 2018 Mar 7;10(3). pii: E68. doi: 10.3390/cancers10030068.

8.

MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer.

Kumari S, Khan S, Gupta SC, Kashyap VK, Yallapu MM, Chauhan SC, Jaggi M.

Oncogenesis. 2018 Feb 22;7(2):19. doi: 10.1038/s41389-018-0031-0.

9.

Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1.

Ganju A, Chauhan SC, Hafeez BB, Doxtater K, Tripathi MK, Zafar N, Yallapu MM, Kumar R, Jaggi M.

Br J Cancer. 2018 Feb 20;118(4):587-599. doi: 10.1038/bjc.2017.431. Epub 2018 Feb 20.

PMID:
29465084
10.

Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.

Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC.

HPB (Oxford). 2018 Jun;20(6):563-572. doi: 10.1016/j.hpb.2017.12.003. Epub 2018 Jan 17.

PMID:
29352660
11.

Quantification of photonic localization properties of targeted nuclear mass density variations: Application in cancer-stage detection.

Sahay P, Ganju A, Almabadi HM, Ghimire HM, Yallapu MM, Skalli O, Jaggi M, Chauhan SC, Pradhan P.

J Biophotonics. 2018 May;11(5):e201700257. doi: 10.1002/jbio.201700257. Epub 2018 Jan 17.

PMID:
29222925
12.

Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages.

Gong Y, Chowdhury P, Midde NM, Rahman MA, Yallapu MM, Kumar S.

Biochem Biophys Rep. 2017 Nov 15;12:214-219. doi: 10.1016/j.bbrep.2017.10.005. eCollection 2017 Dec.

13.

Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications.

Kumar S, Sinha N, Gerth KA, Rahman MA, Yallapu MM, Midde NM.

Biochem Biophys Res Commun. 2017 Sep 23;491(3):675-680. doi: 10.1016/j.bbrc.2017.07.145. Epub 2017 Jul 26.

PMID:
28756226
14.

A mini review on hydrogels classification and recent developments in miscellaneous applications.

Varaprasad K, Raghavendra GM, Jayaramudu T, Yallapu MM, Sadiku R.

Mater Sci Eng C Mater Biol Appl. 2017 Oct 1;79:958-971. doi: 10.1016/j.msec.2017.05.096. Epub 2017 May 15. Review.

PMID:
28629101
15.

miR-145: Revival of a Dragon in Pancreatic Cancer.

Setua S, Khan S, Doxtater K, Yallapu MM, Jaggi M, Chauhan SC.

J Nat Sci. 2017 Mar;3(3). pii: e332.

16.

Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Hafeez BB, Ganju A, Sikander M, Kashyap VK, Hafeez ZB, Chauhan N, Malik S, Massey AE, Tripathi MK, Halaweish FT, Zafar N, Singh MM, Yallapu MM, Chauhan SC, Jaggi M.

Mol Cancer Ther. 2017 Oct;16(10):2267-2280. doi: 10.1158/1535-7163.MCT-17-0157. Epub 2017 Jun 14.

PMID:
28615299
17.

Magnetic nanoformulations for prostate cancer.

Chowdhury P, Roberts AM, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM.

Drug Discov Today. 2017 Aug;22(8):1233-1241. doi: 10.1016/j.drudis.2017.04.018. Epub 2017 May 16. Review.

18.

Disparity in rates of HPV infection and cervical cancer in underserved US populations.

Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, Jaggi M, Chauhan SC.

Front Biosci (Schol Ed). 2017 Jun 1;9:254-269. Review.

19.

Probing mucin interaction behavior of magnetic nanoparticles.

Boya VN, Lovett R, Setua S, Gandhi V, Nagesh PKB, Khan S, Jaggi M, Yallapu MM, Chauhan SC.

J Colloid Interface Sci. 2017 Feb 15;488:258-268. doi: 10.1016/j.jcis.2016.10.090. Epub 2016 Nov 1.

20.

Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.

Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, Yallapu MM, Chauhan SC, Jaggi M.

Sci Rep. 2016 Nov 8;6:36594. doi: 10.1038/srep36594.

21.

miRNA nanotherapeutics for cancer.

Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC, Jaggi M.

Drug Discov Today. 2017 Feb;22(2):424-432. doi: 10.1016/j.drudis.2016.10.014. Epub 2016 Nov 1. Review.

22.

Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy.

Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, Jaggi M, Chauhan SC.

J Gastrointest Surg. 2017 Jan;21(1):94-105. doi: 10.1007/s11605-016-3222-z. Epub 2016 Aug 9.

23.

MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression.

Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, Yallapu MM, Hafeez BB, Ise T, Nagata S, Zafar N, Behrman SW, Wan JY, Ghimire HM, Sahay P, Pradhan P, Chauhan SC, Jaggi M.

Oncogene. 2017 Jan 26;36(4):491-500. doi: 10.1038/onc.2016.218. Epub 2016 Jun 20.

24.

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.

Nagesh PKB, Johnson NR, Boya VKN, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, Jaggi M, Yallapu MM.

Colloids Surf B Biointerfaces. 2016 Aug 1;144:8-20. doi: 10.1016/j.colsurfb.2016.03.071. Epub 2016 Mar 26.

25.

Curcumin Nanoformulation for Cervical Cancer Treatment.

Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, Chauhan SC.

Sci Rep. 2016 Feb 3;6:20051. doi: 10.1038/srep20051.

26.
27.

Therapeutic Applications of Curcumin Nanoformulations.

Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC.

AAPS J. 2015 Nov;17(6):1341-56. doi: 10.1208/s12248-015-9811-z. Epub 2015 Sep 3. Review.

28.

Nanoparticle formulation of ormeloxifene for pancreatic cancer.

Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC.

Biomaterials. 2015;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26.

29.

Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.

Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC.

Cancer Res. 2015 Jun 1;75(11):2292-304. doi: 10.1158/0008-5472.CAN-14-2397. Epub 2015 Apr 3. Erratum in: Cancer Res. 2018 May 1;78(9):2444.

30.

Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles.

Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, Chauhan SC.

Biomaterials. 2015 Apr;46:1-12. doi: 10.1016/j.biomaterials.2014.12.045. Epub 2015 Jan 15.

31.

MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.

Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC.

Oncotarget. 2014 Sep 15;5(17):7599-609.

32.

Slit/Robo pathway: a promising therapeutic target for cancer.

Gara RK, Kumari S, Ganju A, Yallapu MM, Jaggi M, Chauhan SC.

Drug Discov Today. 2015 Jan;20(1):156-64. doi: 10.1016/j.drudis.2014.09.008. Epub 2014 Sep 20. Review.

33.

The roles of cellular nanomechanics in cancer.

Yallapu MM, Katti KS, Katti DR, Mishra SR, Khan S, Jaggi M, Chauhan SC.

Med Res Rev. 2015 Jan;35(1):198-223. doi: 10.1002/med.21329. Epub 2014 Aug 18. Review.

34.

Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.

Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, Chauhan SC.

Biomaterials. 2014 Oct;35(30):8635-48. doi: 10.1016/j.biomaterials.2014.06.040. Epub 2014 Jul 12.

35.

Nanoways to overcome docetaxel resistance in prostate cancer.

Ganju A, Yallapu MM, Khan S, Behrman SW, Chauhan SC, Jaggi M.

Drug Resist Updat. 2014 Apr;17(1-2):13-23. doi: 10.1016/j.drup.2014.04.001. Epub 2014 Apr 5. Review.

36.

Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment.

Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC.

Mol Cancer Ther. 2013 Aug;12(8):1471-80. doi: 10.1158/1535-7163.MCT-12-1227. Epub 2013 May 23.

37.

Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics.

Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC.

Curr Drug Metab. 2013 May;14(4):504-15. Review.

38.

Curcumin nanomedicine: a road to cancer therapeutics.

Yallapu MM, Jaggi M, Chauhan SC.

Curr Pharm Des. 2013;19(11):1994-2010.

39.

Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications.

Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, Kumar D, Jaggi M, Chauhan SC.

Int J Nanomedicine. 2012;7:1761-79. doi: 10.2147/IJN.S29290. Epub 2012 Apr 17.

40.

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes.

Yallapu MM, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC.

Int J Nanomedicine. 2011;6:2779-90. doi: 10.2147/IJN.S25534. Epub 2011 Nov 8.

41.

Curcumin nanoformulations: a future nanomedicine for cancer.

Yallapu MM, Jaggi M, Chauhan SC.

Drug Discov Today. 2012 Jan;17(1-2):71-80. doi: 10.1016/j.drudis.2011.09.009. Epub 2011 Sep 18. Review.

42.

Design of curcumin loaded cellulose nanoparticles for prostate cancer.

Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC.

Curr Drug Metab. 2012 Jan;13(1):120-8.

43.

Design and engineering of nanogels for cancer treatment.

Yallapu MM, Jaggi M, Chauhan SC.

Drug Discov Today. 2011 May;16(9-10):457-63. doi: 10.1016/j.drudis.2011.03.004. Epub 2011 Mar 23. Review.

44.

Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy.

Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M, Chauhan SC.

Biomaterials. 2011 Mar;32(7):1890-905. doi: 10.1016/j.biomaterials.2010.11.028. Epub 2010 Dec 16.

45.

PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications.

Yallapu MM, Foy SP, Jain TK, Labhasetwar V.

Pharm Res. 2010 Nov;27(11):2283-95. doi: 10.1007/s11095-010-0260-1. Epub 2010 Sep 16.

46.

Scope of nanotechnology in ovarian cancer therapeutics.

Yallapu MM, Jaggi M, Chauhan SC.

J Ovarian Res. 2010 Aug 6;3:19. doi: 10.1186/1757-2215-3-19.

47.

Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.

Yallapu MM, Gupta BK, Jaggi M, Chauhan SC.

J Colloid Interface Sci. 2010 Nov 1;351(1):19-29. doi: 10.1016/j.jcis.2010.05.022. Epub 2010 May 12.

PMID:
20627257
48.

Poly(β-cyclodextrin)/curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells.

Yallapu MM, Jaggi M, Chauhan SC.

Macromol Biosci. 2010 Oct 8;10(10):1141-51. doi: 10.1002/mabi.201000084.

PMID:
20572274
49.

beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells.

Yallapu MM, Jaggi M, Chauhan SC.

Colloids Surf B Biointerfaces. 2010 Aug 1;79(1):113-25. doi: 10.1016/j.colsurfb.2010.03.039. Epub 2010 Apr 3.

PMID:
20456930
50.

Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.

Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC.

J Ovarian Res. 2010 Apr 29;3:11. doi: 10.1186/1757-2215-3-11.

Supplemental Content

Loading ...
Support Center